Molecular Medicine Tri-Conference | GenomeWeb

Molecular Medicine Tri-Conference

The company sees microRNAs as the ideal blood-based biomarker for diagnosing and monitoring a number of diseases at the point of care and in the developing world.

PATH is designed to help users combine and use clinical and genomic information to stratify patients as part of efforts to develop more tailored therapies.

Under the terms of the agreement, the companies will combine software products and data to improve NGS analysis and interpretation

MiRxes, a Singapore-based startup focusing on microRNA research and diagnostics, officially launched earlier this month with a proprietary qPCR platform for identifying microRNA and other small RNA biomarkers.

Researchers from the University of California, San Francisco and the California Institute for Quantitative Biosciences have developed a method dubbed PCR-activated cell sorting (PACS) to sort and analyze single cells from large populations of heterogeneous cells based on gene exp

SAN FRANCISCO — Researchers from the University of Medicine and Dentistry of New Jersey and New Jersey Medical School this week unveiled a new qPCR-based mutation-detection chemistry at Cambridge Healthtech Institute's Molecular Medicine Tri-Conference held here.

SAN FRANCISCO — Scientists in the laboratory of Mike Makrigiorgos of the Dana Farber Cancer Institute and Harvard Medical School have developed a method that enriches unknown mutations of targeted DNA sequences based purely on thermal denaturation of DNA heteroduplexes without th

With the offering, Accelrys joins a number of informatics firms that want to exploit the growing NGS market, but the company views the product as a complement to existing offerings, not a rival to them.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.